Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2017

28.11.2016 | Gynecologic Oncology

Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies

verfasst von: Violante Di Donato, MD, PhD, Evangelos Kontopantelis, PhD, Giovanni Aletti, MD, Assunta Casorelli, MD, Ilaria Piacenti, MD, Giorgio Bogani, MD, Francesca Lecce, MD, Pierluigi Benedetti Panici, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary cytoreductive surgery (PDS) followed by platinum-based chemotherapy is the cornerstone of treatment and the absence of residual tumor after PDS is universally considered the most important prognostic factor. The aim of the present analysis was to evaluate trend and predictors of 30-day mortality in patients undergoing primary cytoreduction for ovarian cancer.

Methods

Literature was searched for records reporting 30-day mortality after PDS. All cohorts were rated for quality. Simple and multiple Poisson regression models were used to quantify the association between 30-day mortality and the following: overall or severe complications, proportion of patients with stage IV disease, median age, year of publication, and weighted surgical complexity index. Using the multiple regression model, we calculated the risk of perioperative mortality at different levels for statistically significant covariates of interest.

Results

Simple regression identified median age and proportion of patients with stage IV disease as statistically significant predictors of 30-day mortality. When included in the multiple Poisson regression model, both remained statistically significant, with an incidence rate ratio of 1.087 for median age and 1.017 for stage IV disease. Disease stage was a strong predictor, with the risk estimated to increase from 2.8% (95% confidence interval 2.02–3.66) for stage III to 16.1% (95% confidence interval 6.18–25.93) for stage IV, for a cohort with a median age of 65 years.

Conclusions

Metaregression demonstrated that increased age and advanced clinical stage were independently associated with an increased risk of mortality, and the combined effects of both factors greatly increased the risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Bristow RE, Eisenhauer EL, Santillan A, et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007;104:480–90.CrossRefPubMed Bristow RE, Eisenhauer EL, Santillan A, et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007;104:480–90.CrossRefPubMed
3.
Zurück zum Zitat Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRefPubMed Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRefPubMed
4.
Zurück zum Zitat Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120:23–8.CrossRefPubMed Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120:23–8.CrossRefPubMed
5.
Zurück zum Zitat Gerestein CG Nieuwenhuyzen-de Boer GM, Eijkemans MJ, et al. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer. 2010;46:102–9.CrossRef Gerestein CG Nieuwenhuyzen-de Boer GM, Eijkemans MJ, et al. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer. 2010;46:102–9.CrossRef
6.
Zurück zum Zitat Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983;61:413–20.PubMed Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983;61:413–20.PubMed
7.
Zurück zum Zitat Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol. 1984;18:293–8.CrossRefPubMed Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol. 1984;18:293–8.CrossRefPubMed
8.
Zurück zum Zitat Piver MS, Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol. 1986;24:1–8.CrossRefPubMed Piver MS, Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol. 1986;24:1–8.CrossRefPubMed
9.
Zurück zum Zitat Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol. 1985;20:190–5.CrossRefPubMed Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol. 1985;20:190–5.CrossRefPubMed
10.
Zurück zum Zitat Heintz AP, Hacker NF, Berek JS, et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986;67:783–8.CrossRefPubMed Heintz AP, Hacker NF, Berek JS, et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986;67:783–8.CrossRefPubMed
11.
Zurück zum Zitat Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol. 1992;79:168–72.PubMed Venesmaa P, Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol. 1992;79:168–72.PubMed
12.
Zurück zum Zitat Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47:203–9.CrossRefPubMed Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47:203–9.CrossRefPubMed
13.
Zurück zum Zitat Marchetti DL, Lele SB, Priore RL, et al. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol. 1993;49:86–91.CrossRefPubMed Marchetti DL, Lele SB, Priore RL, et al. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol. 1993;49:86–91.CrossRefPubMed
14.
Zurück zum Zitat Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 1994;53:326–30.CrossRefPubMed Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 1994;53:326–30.CrossRefPubMed
15.
Zurück zum Zitat Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–8.CrossRefPubMed Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–8.CrossRefPubMed
16.
Zurück zum Zitat Liu PC, Benjamin I, Morgan MA, et al. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol. 1997;64:4–8.CrossRefPubMed Liu PC, Benjamin I, Morgan MA, et al. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol. 1997;64:4–8.CrossRefPubMed
17.
Zurück zum Zitat Michel G, De Iaco P, Castaigne D. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 1997;18:9–15.PubMed Michel G, De Iaco P, Castaigne D. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 1997;18:9–15.PubMed
18.
Zurück zum Zitat Lichtenegger W, Sehouli J, Buchmann E, et al. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res. 1998;24:447–51.CrossRefPubMed Lichtenegger W, Sehouli J, Buchmann E, et al. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res. 1998;24:447–51.CrossRefPubMed
19.
Zurück zum Zitat Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–87.CrossRefPubMed Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–87.CrossRefPubMed
20.
Zurück zum Zitat Suzuki M, Ohwada M, Sekiguchi I, et al. Radical cytoreductive surgery combined with platinums—carboplatin and cisplatin chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer. 1999;9:54–60.CrossRefPubMed Suzuki M, Ohwada M, Sekiguchi I, et al. Radical cytoreductive surgery combined with platinums—carboplatin and cisplatin chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer. 1999;9:54–60.CrossRefPubMed
21.
Zurück zum Zitat Naik R, Nordin A, Cross PA, et al. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol. 2000;78:171–5.CrossRefPubMed Naik R, Nordin A, Cross PA, et al. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol. 2000;78:171–5.CrossRefPubMed
22.
Zurück zum Zitat Bristow RE, Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol. 2001;83:39–48.CrossRefPubMed Bristow RE, Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol. 2001;83:39–48.CrossRefPubMed
23.
Zurück zum Zitat Gillette-Cloven N, Burger RA, Monk BJ, et al. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg. 2001;193:626–32.CrossRefPubMed Gillette-Cloven N, Burger RA, Monk BJ, et al. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg. 2001;193:626–32.CrossRefPubMed
24.
Zurück zum Zitat Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390–6.CrossRefPubMed Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390–6.CrossRefPubMed
25.
Zurück zum Zitat Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650–4.CrossRefPubMed Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650–4.CrossRefPubMed
26.
Zurück zum Zitat Ayhan A, Al RA, Baykal C, et al. The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14:51–6.CrossRefPubMed Ayhan A, Al RA, Baykal C, et al. The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14:51–6.CrossRefPubMed
27.
Zurück zum Zitat Cliby W, Dowdy S, Feitoza SS, et al. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol. 2004;94:655–60.CrossRefPubMed Cliby W, Dowdy S, Feitoza SS, et al. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol. 2004;94:655–60.CrossRefPubMed
28.
Zurück zum Zitat Eltabbakh GH, Mount SL, Beatty B, et al. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol. 2004;95:377–83.CrossRefPubMed Eltabbakh GH, Mount SL, Beatty B, et al. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol. 2004;95:377–83.CrossRefPubMed
29.
Zurück zum Zitat Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005;99:608–14.CrossRefPubMed Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005;99:608–14.CrossRefPubMed
30.
Zurück zum Zitat Soegaard Andersen E, Knudsen A, Svarrer T, et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol Oncol. 2005;99:552–6.CrossRefPubMed Soegaard Andersen E, Knudsen A, Svarrer T, et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol Oncol. 2005;99:552–6.CrossRefPubMed
31.
Zurück zum Zitat Aletti GD, Dowdy SC, Podratz KC, et al. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006;100:283–7.CrossRefPubMed Aletti GD, Dowdy SC, Podratz KC, et al. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006;100:283–7.CrossRefPubMed
32.
Zurück zum Zitat Estes JM, Leath CA, Straughn JM, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006;203:527–32.CrossRefPubMed Estes JM, Leath CA, Straughn JM, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006;203:527–32.CrossRefPubMed
33.
Zurück zum Zitat Magtibay PM, Adams PB, Silverman MB, et al. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2006;102:369–74.CrossRefPubMed Magtibay PM, Adams PB, Silverman MB, et al. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2006;102:369–74.CrossRefPubMed
34.
Zurück zum Zitat Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006;103:977–84.CrossRefPubMed Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006;103:977–84.CrossRefPubMed
35.
Zurück zum Zitat Cai HB, Zhou YF, Chen HZ, et al. The role of bowel surgery with cytoreduction for epithelial ovarian cancer. Clin Oncol (R Coll Radiol). 2007;19:757–62.CrossRefPubMed Cai HB, Zhou YF, Chen HZ, et al. The role of bowel surgery with cytoreduction for epithelial ovarian cancer. Clin Oncol (R Coll Radiol). 2007;19:757–62.CrossRefPubMed
36.
Zurück zum Zitat Susini T, Amunni G, Busi E, et al. Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer. 2007;17:581–8.CrossRefPubMed Susini T, Amunni G, Busi E, et al. Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer. 2007;17:581–8.CrossRefPubMed
37.
Zurück zum Zitat Gerestein CG, Damhuis RAM, de Vires M, et al. Causes of postoperative mortality after surgery for ovarian cancer. Eur J Cancer. 2009;45:2799–803.CrossRefPubMed Gerestein CG, Damhuis RAM, de Vires M, et al. Causes of postoperative mortality after surgery for ovarian cancer. Eur J Cancer. 2009;45:2799–803.CrossRefPubMed
38.
Zurück zum Zitat Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.CrossRefPubMed Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.CrossRefPubMed
39.
Zurück zum Zitat Chi DS, Palayekar MJ, Sonoda Y, et al. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol. 2008;108:191–4.CrossRefPubMed Chi DS, Palayekar MJ, Sonoda Y, et al. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol. 2008;108:191–4.CrossRefPubMed
40.
Zurück zum Zitat Chéreau E, Rouzier R, Gouy S, et al. Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases. Eur J Surg Oncol. 2011;37:175–80.CrossRefPubMed Chéreau E, Rouzier R, Gouy S, et al. Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases. Eur J Surg Oncol. 2011;37:175–80.CrossRefPubMed
41.
Zurück zum Zitat Thrall MM, Goff BA, Symons RG, et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol. 2011;118:537–47.CrossRefPubMedPubMedCentral Thrall MM, Goff BA, Symons RG, et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol. 2011;118:537–47.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Langstraat C, Aletti GD, Cliby WA. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol. 2011;123:187–91.CrossRefPubMed Langstraat C, Aletti GD, Cliby WA. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol. 2011;123:187–91.CrossRefPubMed
43.
Zurück zum Zitat Rafii A, Stoeckle E, Jean-Laurent M, et al. Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. PLoS One. 2012;7:e39415.CrossRefPubMedPubMedCentral Rafii A, Stoeckle E, Jean-Laurent M, et al. Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. PLoS One. 2012;7:e39415.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124:10–4.CrossRefPubMed Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124:10–4.CrossRefPubMed
45.
Zurück zum Zitat Markauskas A, Mogensen O, dePont Christensen R, et al. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter? Int J Gynecol Cancer. 2014;24:1420–8.CrossRefPubMed Markauskas A, Mogensen O, dePont Christensen R, et al. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter? Int J Gynecol Cancer. 2014;24:1420–8.CrossRefPubMed
46.
Zurück zum Zitat Benedetti Panici P, Di Donato V, Fischetti M, et al. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: analysis and management of complications in upper abdominal surgery. Gynecol Oncol. 2015;137:406–11.CrossRefPubMed Benedetti Panici P, Di Donato V, Fischetti M, et al. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: analysis and management of complications in upper abdominal surgery. Gynecol Oncol. 2015;137:406–11.CrossRefPubMed
47.
Zurück zum Zitat Patankar S, Burke WM, Hou JY, et al. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. Gynecol Oncol. 2015;138:62–9.CrossRefPubMedPubMedCentral Patankar S, Burke WM, Hou JY, et al. Risk stratification and outcomes of women undergoing surgery for ovarian cancer. Gynecol Oncol. 2015;138:62–9.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Tozzi R, Giannice R, Cianci S, et al. Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of visceral–peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol. 2015;138:252–8.CrossRefPubMed Tozzi R, Giannice R, Cianci S, et al. Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of visceral–peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol. 2015;138:252–8.CrossRefPubMed
49.
Zurück zum Zitat Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.CrossRefPubMed Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.CrossRefPubMed
50.
Zurück zum Zitat Mahdi H, Wiechert A, Lockhart D, et al. Impact of age on 30-day mortality and morbidity in patients undergoing surgery for ovarian cancer. Int J Gynecol Cancer. 2015;25:1216–23.CrossRefPubMed Mahdi H, Wiechert A, Lockhart D, et al. Impact of age on 30-day mortality and morbidity in patients undergoing surgery for ovarian cancer. Int J Gynecol Cancer. 2015;25:1216–23.CrossRefPubMed
51.
Zurück zum Zitat Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7.CrossRefPubMed Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7.CrossRefPubMed
52.
Zurück zum Zitat Ataseven B, Grimm C, Harter P, et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol. 2016;140:215–20.CrossRefPubMed Ataseven B, Grimm C, Harter P, et al. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol. 2016;140:215–20.CrossRefPubMed
53.
Zurück zum Zitat Chiva L, Lapuente F, Castellanos T, et al. What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer? Ann Surg Oncol. 2016;23:1666–73.CrossRefPubMed Chiva L, Lapuente F, Castellanos T, et al. What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer? Ann Surg Oncol. 2016;23:1666–73.CrossRefPubMed
54.
Zurück zum Zitat Aletti GD, Dowdy SC, Podratz KC, et al. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007;105:84–9.CrossRefPubMed Aletti GD, Dowdy SC, Podratz KC, et al. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007;105:84–9.CrossRefPubMed
55.
Zurück zum Zitat Ataseven B, du Bois A, Reinthaller A, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;138:560–5.CrossRefPubMed Ataseven B, du Bois A, Reinthaller A, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;138:560–5.CrossRefPubMed
56.
Zurück zum Zitat Artero A, Zaragoza R, Camarena JJ, et al. Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. J Crit Care. 2010;25:276–81.CrossRefPubMed Artero A, Zaragoza R, Camarena JJ, et al. Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. J Crit Care. 2010;25:276–81.CrossRefPubMed
57.
Zurück zum Zitat Telem DA, Chin EH, Nguyen SQ, et al. Risk factors for anastomotic leak following colorectal surgery: a case–control study. Arch Surg. 2010;145:371–6.CrossRefPubMed Telem DA, Chin EH, Nguyen SQ, et al. Risk factors for anastomotic leak following colorectal surgery: a case–control study. Arch Surg. 2010;145:371–6.CrossRefPubMed
58.
Zurück zum Zitat Sorensen TH, Mellemkjaer Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50.CrossRefPubMed Sorensen TH, Mellemkjaer Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50.CrossRefPubMed
59.
Zurück zum Zitat Monreal M, Lensing AWA, Prins M, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Throm Haemost. 2004;2:876–81.CrossRef Monreal M, Lensing AWA, Prins M, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Throm Haemost. 2004;2:876–81.CrossRef
60.
Zurück zum Zitat Gunderson CC, Thomas ED, Slaughter KN, et al. The survival detriment of venous thromboembolism with epithelial ovarian cancer. Gynecol Oncol. 2014;134:73–7.CrossRefPubMed Gunderson CC, Thomas ED, Slaughter KN, et al. The survival detriment of venous thromboembolism with epithelial ovarian cancer. Gynecol Oncol. 2014;134:73–7.CrossRefPubMed
61.
Zurück zum Zitat Fotopoulou C, duBois A, Karavas AN, et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26:2683–9.CrossRefPubMed Fotopoulou C, duBois A, Karavas AN, et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26:2683–9.CrossRefPubMed
63.
Zurück zum Zitat Uppal S, Igwe E, Rice LW, et al. Frailty index predicts severe complications in gynecologic oncology patients. Gynecol Oncol. 2015;137:98–101.CrossRefPubMed Uppal S, Igwe E, Rice LW, et al. Frailty index predicts severe complications in gynecologic oncology patients. Gynecol Oncol. 2015;137:98–101.CrossRefPubMed
64.
Zurück zum Zitat de Vries NM, Staal JB, van Ravensberg CD, et al. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev. 2011;10:104–14.CrossRefPubMed de Vries NM, Staal JB, van Ravensberg CD, et al. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev. 2011;10:104–14.CrossRefPubMed
65.
Zurück zum Zitat Kristjansson SR, Nesbakken A, Jordhøy MS, et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. Crit Rev Oncol Hematol. 2010;76:208–17.CrossRefPubMed Kristjansson SR, Nesbakken A, Jordhøy MS, et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. Crit Rev Oncol Hematol. 2010;76:208–17.CrossRefPubMed
Metadaten
Titel
Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies
verfasst von
Violante Di Donato, MD, PhD
Evangelos Kontopantelis, PhD
Giovanni Aletti, MD
Assunta Casorelli, MD
Ilaria Piacenti, MD
Giorgio Bogani, MD
Francesca Lecce, MD
Pierluigi Benedetti Panici, MD
Publikationsdatum
28.11.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5680-7

Weitere Artikel der Ausgabe 6/2017

Annals of Surgical Oncology 6/2017 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.